Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewGene Editing Technology Service Provider Nvelop Therapeutics Secures $100 Million in Seed FundingOn September 25, gene editing technology service provider Nvelop Therapeutics secured $100 million in seed funding. This round was led by Newpath Partners, with investments from Atlas Venture, F-Prime Capital, and 5AM Ventures. The funds will primarily be used to advance the company's gene therapy pipeline and establish manufacturing facilities.MitrAssist Lifesciences Completes Nearly 100 Million USD in Series C Financing for Cardiovascular Innovative Medical Device DevelopmentOn September 27, MitrAssist Lifesciences, a cardiovascular innovative medical device developer, completed a nearly US$100 million Series C financing round, jointly led by existing shareholders Centurium Capital and 6 Dimensions Capital. Investors such as Shanghai Jiading State-owned Assets, Hefei Haiheng Capital, Hefei Industrial Investment Capital, Anyuan Fund, and Binhu Science City also participated. The funds will be used to promote the research, development, and industrialization of MitrAssist Lifesciences' innovative cardiovascular products in the structural heart field.Dr. Mayson Completes Over 300 Million Yuan in Series D Financing as a Provider of Medical Artificial Intelligence SolutionsOn September 26, Dr. Mayson, a provider of medical artificial intelligence solutions, announced the completion of a D-round financing of over 300 million yuan. This round of financing was led by Champion Capital, with participation from Runzhang Venture Capital, Suzhou Yhe, and other well-known investment institutions. The existing shareholder, Qiming Venture Capital, continued its investment. The company is seizing the payment reform driven by DRG/DIP to improve medical quality, control the rapid growth of medical insurance costs, monitor the rationality of medical resource consumption, and continuously enhance patient experience.Medical Robot Developer Diligent Robotics Secures $25 Million in New FundingOn September 22, medical robot developer Diligent Robotics secured $25 million in new funding. The round was led by Canaan, with participation from True Ventures, DNX Ventures, Next Coast Ventures, and others. The company will use the funds to accelerate the nationwide expansion of the Moxi robot across hospital systems in China, enhance product development, and triple its market coverage.Health Benefits Platform Provider Take Command Health Raises $25 Million in FinancingOn September 19, health benefits platform provider Take Command Health raised $25 million in funding, led by Edison Partners with participation from LiveOak Venture Partners and SJF Ventures. The company will use the funds to expand its market presence, enhance payment functionalities on its platform, and develop new products.Gene Editing Product Developer Qihan Bio Completes Over 100 Million Yuan Pre-B Round FinancingOn September 22, Qihan Biotech, a gene-editing product developer, completed a Pre-B round of financing exceeding 100 million yuan. This round of financing was participated in by Zhejiang Provincial Industrial Fund Co., Ltd. and existing investors. The funds from this round of financing will be used to support Qihan Biotech's rapid product iteration and global development of gene-edited stem cell products over the next four years.A&T Bio Completes Nearly RMB100 Million A+ Round Financing as a CDMO Service Provider for ConsumablesOn September 19, Yatong Biotech announced the completion of a nearly RMB 100 million Series A+ financing round, led by Qian Dao Fund with participation from Borun Capital. WinX Capital continued to serve as the exclusive financial advisor. The proceeds from this round will mainly be used for the expansion of the company’s high-end product pipeline, R&D in raw materials and material modification, the provision of leading consumables CDMO services, and the establishment of comprehensive international channels.Blockchain Data Platform Briya Completes $11.5 Million Series A FinancingOn September 19, blockchain medical data exchange platform Briya announced the completion of a $11.5 million Series A financing round, led by Team8, with participation from existing investors Insight Partners, Amiti Ventures, and Innocare Health Investments, and follow-up investment from the George Kaiser Family Foundation. The funds will support Briya in transforming the way healthcare organizations and life science organizations exchange data, with a particular focus on supporting the health ecosystem in the United States.Clinical Trial Participant Management Platform Mural Health Secures $8 Million in Seed FundingOn September 19, Mural Health, a clinical trial participant management platform, secured $8 million in seed funding. This round was led by Bessemer Venture Partners, with participation from Virtue VC, Operator Partners, Arkitect Ventures, Correlation Ventures, and Project Mayhem Ventures. The company plans to use the proceeds from this round to expand its platform to modernize the clinical trial participant experience.AI Clinical Trial and Research Management Platform Medeloop Completes $8 Million Seed FinancingOn September 21, Medeloop, an AI clinical trial and research management platform, completed an $8 million seed funding round led by General Catalyst, with participation from Maven Ventures, Ovo Fund, NV Investments, and others. The company plans to use the funds to launch an end-to-end solution for early-stage clinical research.Patient Engagement and Access Solutions Provider Amenities Health Raises $6.25 Million in Series A FundingOn September 20, patient engagement and access solutions provider Amenities Health secured a $6.25 million Series A funding round, bringing its total Series A funding to $10 million. The round was led by MemorialCare Innovation Fund and Epic Ventures. The company will use the funds to further accelerate the rollout of its Digital Front Door platform, helping healthcare systems improve medical services and deliver personalized patient experiences.Substance Use Disorder Treatment Program Provider NorthStar Care Completes $6 Million Seed Financing RoundOn September 21, NorthStar Care, a virtual substance use disorder treatment program, completed a $6 million seed funding round, led by Tony Robbins and Starting Line. The funds will be used for business expansion and market promotion.HealNow, an online pharmacy payment solutions provider, secures $5.5 million in seed fundingOn September 20, HealNow, an online pharmacy payment solutions provider, secured $5.5 million in seed funding led by Bonfire Ventures. Other investors participating in this round include Walkabout Ventures, Remarkable Ventures, Alabama Futures Fund, and Impulsum Ventures. The funds will primarily be used for the company’s business expansion and market promotion.02 Digital Health Industry Dynamics
PeptiDream Partners with Genentech, a Member of the Roche GroupOn September 21, PeptiDream announced a new multi-target collaboration and licensing agreement with Genentech, a subsidiary of Roche, worth up to $1 billion. The partnership will focus on the joint discovery and development of novel macrocyclic peptide-radiosotope conjugates.Merck Collaborates with AI Companies BenevolentAI and ExscientiaOn September 20, Germany's Merck entered into two separate AI drug discovery collaborations with artificial intelligence (AI) companies BenevolentAI and Exscientia, respectively, focusing on three targets in oncology, neurology, and immunology. The former collaboration involves payments of $594 million, while the latter involves payments of $694 million.Orionis Biosciences Partners with Genentech, a Member of the Roche GroupOn September 20, Orionis Biosciences announced a multi-year collaboration with Genentech, a subsidiary of Roche, worth up to $2 billion. The partnership will focus on discovering novel molecular glue drugs targeting challenging targets in significant disease areas, including oncology and neurodegenerative diseases.03 Global Digital Health M&A OverviewBoston Scientific Acquires Relevant for Over $850 MillionRecently, Boston Scientific announced an acquisition agreement with Relevant Medsystems. The transaction includes $850 million in upfront cash plus undisclosed milestone payments based on sales performance over the next three years. Boston Scientific expects Relievant's sales to exceed $70 million in 2023, with a year-over-year growth rate of over 50% in 2024. Relievant primarily develops and sells the Intracept® Intraosseous Nerve Ablation System for treating vertebrogenic pain (a form of chronic lower back pain).Lupin Acquires Five Drug Brands from MenariniOn September 22, Lupin signed an agreement to acquire five legacy brands from Menarini: Piclin (sodium picosulfate), Menoctyl (octylonium bromide), Sucramal O (sucralfate + oxytacaine), Pyridium (phenazopyridine), and Distaclor (cefaclor), covering the fields of gastroenterology, urology, and anti-infectives, along with the associated trademarks. Since July 2021, Lupin has been exclusively marketing these brands in India under a distribution and promotion agreement with A. Menarini India. This acquisition marks a significant step forward for Lupin, representing an important move in expanding its business presence in the Indian market.Artery Network/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.
Compiled by: Zhang Qiankun
